Seven reasons the beleaguered biotech sector is now a ‘buy’
June 17, 2022 at 10:17 AM EDT
Investors ought to take advantage of low prices for a long-term view.
Seven reasons the beleaguered biotech sector is now a ‘buy’
By:
MarketWatch
June 17, 2022 at 10:17 AM EDT
Investors ought to take advantage of low prices for a long-term view.
Related Stocks:
Alnylam Pharmaceuticals
Baxter International
Biogen Idec
Boston Scientific
Bristol-Myers Squibb
Cardinal Health
Gilead Sciences
Johnson & Johnson
Karuna Therapeutics Inc
Medtronic
Mirati Therapeutics
Natera Inc
Roche Holding AG Basel American Depositary Shares
S&P Biotech SPDR
Stryker Corp
Turning Point Therapeutics Inc
Vertex Pharmaceuticals
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|